Development of SEP-363856, a TAAR1/5-HT1A Agonist for the Treatment of Schizophrenia

Time: 11:50 am
day: Day One

Details:

• Summary of the discovery of SEP-363856 and its novel non-D2 based mechanism of action for the treatment of schizophrenia
• Rationale for development of a non-D2 agent for the treatment of schizophrenia: importance and implications
• Overview of clinical trial data to date, and status update of our Phase 3 clinical development program

Speakers: